Proteomic profiling of the cancer cell secretome: informing clinical research

References

• Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–527.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights. 2007;1:1–48.
   Google Scholar
• Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation–quality assurance and control of protein biomarker assays. Mol Oncol. 2014;8(4):840–858.
   PubMed Web of Science ®Google Scholar
• Pagel O, Loroch S, Sickmann A, et al. Current strategies and findings in clinically relevant post-translational modification-specific proteomics. Expert Rev Proteomics. 2015;12(3):235–253.
   PubMed Web of Science ®Google Scholar
• Surinova S, Schiess R, Huttenhain R, et al. On the development of plasma protein biomarkers. J Proteome Res. 2011;10(1):5–16.
   PubMed Web of Science ®Google Scholar
• Ray S, Reddy PJ, Jain R, et al. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics. 2011;11(11):2139–2161.
   PubMed Web of Science ®Google Scholar
• Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics. 2008;7(10):1850–1862.
   PubMed Web of Science ®Google Scholar
• Yakob M, Fuentes L, Wang MB, et al. Salivary biomarkers for detection of oral squamous cell carcinoma - current state and recent advances. Curr Oral Health Rep. 2014;1(2):133–141.
   PubMedGoogle Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1(11):845–867.
   PubMed Web of Science ®Google Scholar
• Chen YT, Chen HW, Domanski D, et al. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J Proteomics. 2012;75(12):3529–3545.
   PubMed Web of Science ®Google Scholar
• Tang HY, Ali-Khan N, Echan LA, et al. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics. 2005;5(13):3329–3342.
   PubMed Web of Science ®Google Scholar
• Yocum AK, Yu K, Oe T, et al. Effect of immunoaffinity depletion of human serum during proteomic investigations. J Proteome Res. 2005;4(5):1722–1731.
   PubMed Web of Science ®Google Scholar
• Yu KH, Barry CG, Austin D, et al. Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J Proteome Res. 2009;8(3):1565–1576.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chien KY, Tsang NM, et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics. 2005;5(12):3173–3182.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chen HC, Chen SJ, et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics. 2008;8(2):316–332.
   PubMed Web of Science ®Google Scholar
• Weng LP, Wu CC, Hsu BL, et al. Secretome-based identification of Mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. J Proteome Res. 2008;7(9):3765–3775.
   PubMed Web of Science ®Google Scholar
• Wu CC, Hsu CW, Chen CD, et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics. 2010;9(6):1100–1117.
   PubMed Web of Science ®Google Scholar
• Chang KP, Wu CC, Chen HC, et al. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics. 2010;10(14):2644–2660.
   PubMed Web of Science ®Google Scholar
• Chang YT, Wu CC, Shyr YM, et al. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One. 2011;6(5):e20029.
   PubMed Web of Science ®Google Scholar
• Wang CI, Wang CL, Wang CW, et al. Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome. Int J Cancer. 2011;128(10):2364–2372.
   PubMed Web of Science ®Google Scholar
• Yu CJ, Chang KP, Chang YJ, et al. Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis. J Proteome Res. 2011;10(8):3778–3788.
   PubMed Web of Science ®Google Scholar
• Lin SJ, Chang KP, Hsu CW, et al. Low-molecular-mass secretome profiling identifies C-C motif chemokine 5 as a potential plasma biomarker and therapeutic target for nasopharyngeal carcinoma. J Proteomics. 2013;94:186–201.
   PubMed Web of Science ®Google Scholar
• Hsu CW, Yu JS, Peng PH, et al. Secretome profiling of primary cells reveals that THBS2 is a salivary biomarker of oral cavity squamous cell carcinoma. J Proteome Res. 2014;13(11):4796–4807.
   PubMed Web of Science ®Google Scholar
• Chang KP, Lin SJ, Liu SC, et al. Low-molecular-mass secretome profiling identifies HMGA2 and MIF as prognostic biomarkers for oral cavity squamous cell carcinoma. Sci Rep. 2015;5:11689.
   PubMed Web of Science ®Google Scholar
• Volmer MW, Radacz Y, Hahn SA, et al. Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: landscaping activity of Smad4 as revealed by a “secretome” analysis. Proteomics. 2004;4(5):1324–1334.
   PubMed Web of Science ®Google Scholar
• Gronborg M, Kristiansen TZ, Iwahori A, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 2006;5(1):157–171.
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Diamandis EP. Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics. 2007;6(11):1997–2011.
   PubMed Web of Science ®Google Scholar
• Piersma SR, Fiedler U, Span S, et al. Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res. 2010;9(4):1913–1922.
   PubMed Web of Science ®Google Scholar
• Xue H, Lu B, Lai M. The cancer secretome: a reservoir of biomarkers. J Transl Med. 2008;6:52.
   Web of Science ®Google Scholar
• Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J Proteomics. 2010;73(12):2291–2305.
   PubMed Web of Science ®Google Scholar
• Pavlou MP, Diamandis EP. The cancer cell secretome: a good source for discovering biomarkers? J Proteomics. 2010;73(10):1896–1906.
   PubMed Web of Science ®Google Scholar
• Schaaij-Visser TB, de Wit M, Lam SW, et al. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta. 2013;1834(11):2242–2258.
   PubMed Web of Science ®Google Scholar
• Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752–3756.
   PubMed Web of Science ®Google Scholar
• Richter R, Schulz-Knappe P, Schrader M, et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B Biomed Sci Appl. 1999;726(1–2):25–35.
   PubMed Web of Science ®Google Scholar
• Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 1994;54(8):2136–2140.
   PubMed Web of Science ®Google Scholar
• Chang KP, Hao SP, Chang JH, et al. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res. 2008;14(21):6979–6987.
   PubMed Web of Science ®Google Scholar
• Strojan P, Budihna M, Smid L, et al. Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. Neoplasma. 2001;48(1):66–71.
   PubMed Web of Science ®Google Scholar
• Triantafillidis JK, Merikas E, Govosdis V, et al. Increased fasting serum levels of growth hormone and gastrin in patients with gastric and large bowel cancer. Hepatogastroenterology. 2003;50(Suppl 2):cclvi–cclx.
   PubMedGoogle Scholar
• Tsukishiro S, Suzumori N, Nishikawa H, et al. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol. 2005;96(2):516–519.
   PubMed Web of Science ®Google Scholar
• Tirumalai RS, Chan KC, Prieto DA, et al. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics. 2003;2(10):1096–1103.
   PubMed Web of Science ®Google Scholar
• Greening DW, Simpson RJ. A centrifugal ultrafiltration strategy for isolating the low-molecular weight (<or=25K) component of human plasma proteome. J Proteomics. 2010;73(3):637–648.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Akiyama H, Kuroda T, et al. A novel approach and protocol for discovering extremely low-abundance proteins in serum. Proteomics. 2006;6(17):4845–4855.
   PubMed Web of Science ®Google Scholar
• Camerini S, Polci ML, Liotta LA, et al. A method for the selective isolation and enrichment of carrier protein-bound low-molecular weight proteins and peptides in the blood. Proteomics Clin Appl. 2007;1(2):176–184.
   PubMed Web of Science ®Google Scholar
• Kay R, Barton C, Ratcliffe L, et al. Enrichment of low molecular weight serum proteins using acetonitrile precipitation for mass spectrometry based proteomic analysis. Rapid Commun Mass Spectrom. 2008;22(20):3255–3260.
   PubMed Web of Science ®Google Scholar
• Bouamrani A, Hu Y, Tasciotti E, et al. Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics. 2010;10(3):496–505.
   PubMed Web of Science ®Google Scholar
• Capriotti AL, Caruso G, Cavaliere C, et al. Comparison of three different enrichment strategies for serum low molecular weight protein identification using shotgun proteomics approach. Anal Chim Acta. 2012;740:58–65.
   Web of Science ®Google Scholar
• Boschetti E, Righetti PG. Low-abundance protein discovery: state of the art and protocols. Amsterdam: Elsevier Inc; 2013.
   Google Scholar
• Eichelbaum K, Winter M, Berriel Diaz M, et al. Selective enrichment of newly synthesized proteins for quantitative secretome analysis. Nat Biotechnol. 2012;30(10):984–990.
   PubMed Web of Science ®Google Scholar
• Cao J, Hu Y, Shen C, et al. Nanozeolite-driven approach for enrichment of secretory proteins in human hepatocellular carcinoma cells. Proteomics. 2009;9(21):4881–4888.
   PubMed Web of Science ®Google Scholar
• Schagger H. Tricine-SDS-PAGE. Nat Protoc. 2006;1(1):16–22.
   PubMed Web of Science ®Google Scholar
• Sepiashvili L, Waggott D, Hui A, et al. Integrated omic analysis of oropharyngeal carcinomas reveals Human Papillomavirus (HPV)–dependent regulation of the activator protein 1 (AP-1) pathway. Mol Cell Proteomics. 2012;11(11):1404–1415.
   PubMed Web of Science ®Google Scholar
• Makawita S, Smith C, Batruch I, et al. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics. 2011;10(10):M111.008599.
   PubMed Web of Science ®Google Scholar
• Xue H, Lü B, Zhang J, et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res. 2010;9(1):545–555.
   PubMed Web of Science ®Google Scholar
• Planque C, Kulasingam V, Smith CR, et al. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics. 2009;8(12):2746–2758.
   PubMed Web of Science ®Google Scholar
• Sardana G, Jung K, Stephan C, et al. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res. 2008;7(8):3329–3338.
   PubMed Web of Science ®Google Scholar
• Gunawardana CG, Kuk C, Smith CR, et al. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J Proteome Res. 2009;8(10):4705–4713.
   PubMed Web of Science ®Google Scholar
• Paulitschke V, Kunstfeld R, Thomas M, et al. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J Proteome Res. 2008;8(5):2501–2510.
   Web of Science ®Google Scholar
• Lawlor K, Apri N, Lacomis L, et al. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J Proteome Res. 2009;8(3):1489–1503.
   PubMed Web of Science ®Google Scholar
• Luo X, Liu Y, Wang R, et al. A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer. J Proteomics. 2011;74(4):528–538.
   PubMed Web of Science ®Google Scholar
• Chang YH, Lee SH, Chang HC, et al. Comparative secretome analyses using a hollow fiber culture system with label-free quantitative proteomics indicates the influence of PARK7 on cell proliferation and migration/invasion in lung adenocarcinoma. J Proteome Res. 2012;11(11):5167–5185.
   PubMed Web of Science ®Google Scholar
• Bendall SC, Hughes C, Campbell L, et al. An enhanced mass spectrometry approach reveals human embryonic stem cell growth factors in culture. Mol Cell Proteomics. 2008;8:421–432.
   PubMed Web of Science ®Google Scholar
• Malard V, Chardan L, Roussi S, et al. Analytical constraints for the analysis of human cell line secretomes by shotgun proteomics. J Proteomics. 2012;75(3):1043–1054.
   PubMed Web of Science ®Google Scholar
• Mange A, Dimitrakopoulos L, Soosaipillai A, et al. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. J Proteomics. 2016;142:114–121.
   PubMed Web of Science ®Google Scholar
• Shin J, Kim HJ, Kim G, et al. Discovery of melanotransferrin as a serological marker of colorectal cancer by secretome analysis and quantitative proteomics. J Proteome Res. 2014;13(11):4919–4931.
   PubMed Web of Science ®Google Scholar
• Karagiannis GS, Pavlou MP, Saraon P, et al. In-depth proteomic delineation of the colorectal cancer exoproteome: mechanistic insight and identification of potential biomarkers. J Proteomics. 2014;103:121–136.
   PubMed Web of Science ®Google Scholar
• Yao L, Lao W, Zhang Y, et al. Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues. J Proteome Res. 2012;11(6):3281–3294.
   PubMed Web of Science ®Google Scholar
• Loei H, Tan HT, Lim TK, et al. Mining the gastric cancer secretome: identification of GRN as a potential diagnostic marker for early gastric cancer. J Proteome Res. 2012;11(3):1759–1772.
   PubMed Web of Science ®Google Scholar
• Sepiashvili L, Hui A, Ignatchenko V, et al. Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy. Mol Cell Proteomics. 2012;11(11):1404–1415.
   PubMed Web of Science ®Google Scholar
• Giovannini C, Minguzzi M, Genovese F, et al. Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. Oncotarget. 2016;7(26):39609–39626.
   PubMed Web of Science ®Google Scholar
• Li X, Jiang J, Zhao X, et al. In-depth analysis of secretome and N-glycosecretome of human hepatocellular carcinoma metastatic cell lines shed light on metastasis correlated proteins. Oncotarget. 2016;7(16):22031–22049.
   PubMed Web of Science ®Google Scholar
• Yang L, Rong W, Xiao T, et al. Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma. Sci China Life Sci. 2013;56(7):638–646.
   PubMed Web of Science ®Google Scholar
• Brandi J, Dalla Pozza E, Dando I, et al. Secretome protein signature of human pancreatic cancer stem-like cells. J Proteomics. 2016;136:1–12.
   PubMed Web of Science ®Google Scholar
• Kramer M, Pierredon S, Ribaux P, et al. Secretome identifies tenascin-X as a potent marker of ovarian cancer. Biomed Res Int. 2015;2015:208017.
   PubMed Web of Science ®Google Scholar
• Barderas R, Mendes M, Torres S, et al. In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. Mol Cell Proteomics. 2013;12(6):1602–1620.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
   PubMed Web of Science ®Google Scholar
• Wang CL, Wang CI, Liao PC, et al. Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J Proteome Res. 2009;8(10):4428–4440.
   PubMed Web of Science ®Google Scholar
• Shin J, Kim G, Lee JW, et al. Identification of ganglioside GM2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes. Cancer Sci. 2016;107(6):828–835.
   PubMed Web of Science ®Google Scholar
• Lin CY, Tsui KH, Yu CC, et al. Searching cell-secreted proteomes for potential urinary bladder tumor markers. Proteomics. 2006;6(15):4381–4389.
   PubMed Web of Science ®Google Scholar
• Mateo F, Meca-Cortes O, Celia-Terrassa T, et al. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Mol Cancer. 2014;13:237.
   PubMed Web of Science ®Google Scholar
• Pang B, Zhang H, Wang J, et al. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression. Prostate. 2009;69(11):1176–1187.
   PubMed Web of Science ®Google Scholar
• Hu R, Huffman KE, Chu M, et al. Quantitative secretomic analysis identifies extracellular protein factors that modulate the metastatic phenotype of non-small cell lung cancer. J Proteome Res. 2016;15(2):477–486.
   PubMed Web of Science ®Google Scholar
• Yao L, Zhang Y, Chen K, et al. Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One. 2011;6(9):e24684.
   PubMed Web of Science ®Google Scholar
• Teng PN, Wang G, Hood BL, et al. Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer. 2014;110(1):123–132.
   PubMed Web of Science ®Google Scholar
• Bateman NW, Jaworski E, Ao W, et al. Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. J Proteome Res. 2015;14(4):1900–1910.
   PubMed Web of Science ®Google Scholar
• Wu J, Qin H, Li T, et al. Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer. Oncotarget. 2016;7(18):25315–25327.
   PubMed Web of Science ®Google Scholar
• Katsila T, Juliachs M, Gregori J, et al. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin Cancer Res. 2014;20(24):6346–6356.
   PubMed Web of Science ®Google Scholar
• Gangoda L, Keerthikumar S, Fonseka P, et al. Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin. Oncotarget. 2015;6(13):11175–11190.
   PubMed Web of Science ®Google Scholar
• Chen SX, Xu XE, Wang XQ, et al. Identification of colonic fibroblast secretomes reveals secretory factors regulating colon cancer cell proliferation. J Proteomics. 2014;110:155–171.
   PubMed Web of Science ®Google Scholar
• Radziwon-Balicka A, Medina C, O’Driscoll L, et al. Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. Br J Pharmacol. 2012;167(4):787–804.
   PubMed Web of Science ®Google Scholar
• Shin SH, Kim J, Heo SC, et al. Proteomic identification of betaig-h3 as a lysophosphatidic acid-induced secreted protein of human mesenchymal stem cells: paracrine activation of A549 lung adenocarcinoma cells by betaig-h3. Mol Cell Proteomics. 2012;11(2):M111 012385.
   PubMed Web of Science ®Google Scholar
• Weiss JV, Klein-Scory S, Kubler S, et al. Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP. Int J Cancer. 2011;128(6):1384–1392.
   PubMed Web of Science ®Google Scholar
• Kashat L, So AK, Masui O, et al. Secretome-based identification and characterization of potential biomarkers in thyroid cancer. J Proteome Res. 2010;9(11):5757–5769.
   PubMed Web of Science ®Google Scholar
• So AK, Kaur J, Kak I, et al. Biotinidase is a novel marker for papillary thyroid cancer aggressiveness. PLoS One. 2012;7(7):e40956.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang Y, Qian Y, et al. Discovery of specific metastasis-related N-glycan alterations in epithelial ovarian cancer based on quantitative glycomics. PLoS One. 2014;9(2):e87978.
   PubMed Web of Science ®Google Scholar
• Bagordakis E, Sawazaki-Calone I, Macedo CC, et al. Secretome profiling of oral squamous cell carcinoma-associated fibroblasts reveals organization and disassembly of extracellular matrix and collagen metabolic process signatures. Tumour Biol. 2016;37(7):9045–9057.
   PubMed Web of Science ®Google Scholar
• Cortesi L, Barchetti A, De Matteis E, et al. Identification of protein clusters predictive of response to chemotherapy in breast cancer patients. J Proteome Res. 2009;8(11):4916–4933.
   PubMed Web of Science ®Google Scholar
• Rasanen K, Sriswasdi S, Valiga A, et al. Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. Mol Cell Proteomics. 2013;12(12):3778–3792.
   PubMed Web of Science ®Google Scholar
• Winiarski BK, Wolanska KI, Rai S, et al. Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling. Transl Oncol. 2013;6(6):703–714.
   PubMed Web of Science ®Google Scholar
• Duluc C, Moatassim-Billah S, Chalabi-Dchar M, et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med. 2015;7(6):735–753.
   PubMed Web of Science ®Google Scholar
• Lee YC, Lin SC, Yu G, et al. Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer. Cancer Res. 2015;75(22):4949–4959.
   PubMed Web of Science ®Google Scholar
• Gromov P, Gromova I, Bunkenborg J, et al. Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol. 2010;4(1):65–89.
   PubMed Web of Science ®Google Scholar
• Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008;111(4):2339–2346.
   PubMed Web of Science ®Google Scholar
• Lou X, Xiao T, Zhao K, et al. Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer. J Proteome Res. 2007;6(3):1083–1092.
   PubMed Web of Science ®Google Scholar
• He J, Gornbein J, Shen D, et al. Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. Int J Oncol. 2007;30(1):145–154.
   PubMed Web of Science ®Google Scholar
• Yamashita R, Fujiwara Y, Ikari K, et al. Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry. Mol Cell Biochem. 2007;298(1–2):83–92.
   PubMed Web of Science ®Google Scholar
• Huang LJ, Chen SX, Luo WJ, et al. Proteomic analysis of secreted proteins of non-small cell lung cancer. Ai Zheng. 2006;25(11):1361–1367.
   PubMedGoogle Scholar
• Moscova M, Marsh DJ, Baxter RC. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res. 2006;66(3):1376–1383.
   PubMed Web of Science ®Google Scholar
• Farag SS, Srivastava S, Messina-Graham S, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 2013;22(7):1007–1015.
   PubMed Web of Science ®Google Scholar
• Markovic SN, Suman VJ, Rao RA, et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007;30(3):303–309.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Jeong J, Guo H, et al. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Med. 2014;3(2):293–299.
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Santegoets SJ, Reyners AK, et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol. 2015;26(10):2141–2149.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kwon HJ, Jung I, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin Cancer Res. 2015;21(3):544–552.
   PubMed Web of Science ®Google Scholar
• Gietema JA, Hoekstra R, De Vos FY, et al. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol. 2006;17(8):1320–1327.
   PubMed Web of Science ®Google Scholar
• Zacarias-Fluck MF, Morancho B, Vicario R, et al. Effect of cellular senescence on the growth of HER2-positive breast cancers. J Natl Cancer Inst. 2015;107:5.
   Google Scholar
• Wojtuszkiewicz A, Schuurhuis GJ, Kessler FL, et al. Exosomes secreted by apoptosis-resistant acute myeloid leukemia (AML) blasts harbor regulatory network proteins potentially involved in antagonism of apoptosis. Mol Cell Proteomics. 2016;15(4):1281–1298.
   PubMed Web of Science ®Google Scholar
• Kraya AA, Piao S, Xu X, et al. Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy. 2015;11(1):60–74.
   PubMed Web of Science ®Google Scholar
• Girotti MR, Fernandez M, Lopez JA, et al. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/alpha2beta1 integrin axis. J Invest Dermatol. 2011;131(12):2438–2447.
   PubMed Web of Science ®Google Scholar
• Park YS, Hwang S, Jin YM, et al. CCN1 secreted by tonsil-derived mesenchymal stem cells promotes endothelial cell angiogenesis via integrin alphav beta3 and AMPK. J Cell Physiol. 2015;230(1):140–149.
   PubMed Web of Science ®Google Scholar
• Nijaguna MB, Patil V, Urbach S, et al. Glioblastoma-derived macrophage colony-stimulating factor (MCSF) induces microglial release of insulin-like growth factor-binding protein 1 (IGFBP1) to promote angiogenesis. J Biol Chem. 2015;290(38):23401–23415.
   PubMed Web of Science ®Google Scholar
• Lee S, Goldfinger LE. RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells. Faseb J. 2014;28(9):4158–4168.
   PubMed Web of Science ®Google Scholar
• Wood LW, Cox NI, Phelps CA, et al. Thyroid transcription factor 1 reprograms angiogenic activities of secretome. Sci Rep. 2016;6:19857.
   PubMed Web of Science ®Google Scholar
• Gopal SK, Greening DW, Zhu HJ, et al. Transformed MDCK cells secrete elevated MMP1 that generates LAMA5 fragments promoting endothelial cell angiogenesis. Sci Rep. 2016;6:28321.
   PubMed Web of Science ®Google Scholar
• Hwang HJ, Jung SH, Lee HC, et al. Identification of novel therapeutic targets in the secretome of ionizing radiation-induced senescent tumor cells. Oncology Reports. 2016;35(2):841–850.
   PubMed Web of Science ®Google Scholar
• Cox TR, Rumney RM, Schoof EM, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522(7554):106–110.
   PubMed Web of Science ®Google Scholar
• Han NK, Kim BC, Lee HC, et al. Secretome analysis of ionizing radiation-induced senescent cancer cells reveals that secreted RKIP plays a critical role in neighboring cell migration. Proteomics. 2012;12(18):2822–2832.
   PubMed Web of Science ®Google Scholar
• Ween MP, Lokman NA, Hoffmann P, et al. Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer. 2011;128(7):1570–1584.
   PubMed Web of Science ®Google Scholar
• Attar-Schneider O, Zismanov V, Drucker L, et al. Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation. Tumour Biol. 2016;37(4):4755–4765.
   PubMed Web of Science ®Google Scholar
• Elghonaimy EA, Ibrahim SA, Youns A, et al. Secretome of tumor-associated leukocytes augment epithelial-mesenchymal transition in positive lymph node breast cancer patients via activation of EGFR/Tyr845 and NF-kappaB/p65 signaling pathway. Tumour Biol. 2016;37(9):12441–12453.
   PubMed Web of Science ®Google Scholar
• Knelson EH, Gaviglio AL, Nee JC, et al. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. J Clin Invest. 2014;124(7):3016–3031.
   PubMed Web of Science ®Google Scholar
• Obenauf AC, Zou Y, Ji AL, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520(7547):368–372.
   PubMed Web of Science ®Google Scholar
• Neilsen PM, Noll JE, Suetani RJ, et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget. 2011;2(12):1203–1217.
   PubMed Web of Science ®Google Scholar
• Zawadzka AM, Schilling B, Cusack MP, et al. Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma. Mol Cell Proteomics. 2014;13(4):1034–1049.
   PubMed Web of Science ®Google Scholar
• Berglund L, Björling E, Oksvold P, et al. A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics. 2008;7(10):2019–2027.
   PubMed Web of Science ®Google Scholar
• Marx V. Finding the right antibody for the job. Nat Methods. 2013;10(8):703–707.
   PubMed Web of Science ®Google Scholar
• Gallien S, Domon B. Advances in high-resolution quantitative proteomics: implications for clinical applications. Expert Rev Proteomics. 2015;12(5):489–498.
   PubMed Web of Science ®Google Scholar
• Chambers AG, Percy AJ, Simon R, et al. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics. 2014;11(2):137–148.
   PubMed Web of Science ®Google Scholar
• Chen CD, Wang CL, Yu CJ, et al. Targeted proteomic pipeline reveals diagnostic biomarkers for malignant pleural effusion of lung cancer. J. Proteome Res. 2014;13(6):2818–2829.
   PubMed Web of Science ®Google Scholar
• Yu JS, Chen YT, Chiang WF, et al. Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan. Proc Natl Acad Sci USA. 2016;113(41):11549–11554.
   PubMed Web of Science ®Google Scholar
• Feizi A, Banaei-Esfahani A, Nielsen J. HCSD: the human cancer secretome database. Database (Oxford). 2015;2015:bav051.
   PubMed Web of Science ®Google Scholar
• Whiteaker JR, Lin C, Kennedy J, et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol. 2011;29(7):625–634.
   PubMed Web of Science ®Google Scholar
• Li XJ, Hayward C, Fong PY, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2013;5(207):207ra142.
   PubMed Web of Science ®Google Scholar